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We investigated the potential correlation between the character-
istics prior transplantation and the subsequent clinical outcomes in
175 consecutive patients who received HSC transplantation from
HLA-mismatched/haploidentical donors. Patients eligible for
study were those with a diagnosis of leukemia, all lacking an HLA
matched sibling or unrelated donor. Patients ranged in age from 6
to 53 years (median 25 years) and donors from 13 to 66 years
(median 40 years). Compatibility testing of family members in-
cluded serology and intermediate resolution DNA typing for
HLA-A, -B, and -C antigens, plus high resolution DNA typing for
HLA-DRB1, -DQB1, and -DPB1. Donors included 72 mothers
(41%), 29 fathers (16.6%), 54 siblings (31%), 16 children (9%), 4
cousins (2.3%), with various grades of HLA disparity: 28 (16%)
with 1; 79 (45%) with 2; 68 (39%) with 3 antigen mismatch. Grafts
(BMPB) was harvested from donor BM collected after four days
of G-CSF, and PB collected after 5 days of G-CSF. The graft was
analyzed for content of CD34 cells and subsets of lymphoid cell
populations, CD3, CD4, CD8, and CD14, using standard-
ized Multi-set kits (Becton-Dickinson, San Jose, CA, USA). All
patients enrolled in this study were treated with a uniform condi-
tioning regimen (BuCy2ATG), given GVHD prophylaxis
(CsA short term MTX), and followed from 36 to 1191days after
transplantation (median 401 days). Univariate analysis for survival
indicated that disease status prior transplantation and donor CD3
cell dose were the only predictors of the 2-year probability of
survival: early disease (77.8%), intermediate disease (38%), and
those with advanced disease (52%), [P0.018]; survival in those
given a CD3 cell dose 150 106/kg was 52% and CD3 cell
dose 150106/kg was 74%, respectively [P0.0215]. This was
conﬁrmed by multivariate analysis: patients transplanted with in-
termediate/advanced stage disease [RR1.568 (95% CI, 1.128-
2.17); P0.007] had a worse overall survival; Infusion of a high
dose of CD3 cells (150  106/kg) had improved survival [0.530
(0.300-0.95); P0.03] without increase the incidence of developing
Grade 3-4 aGVHD [1.27 (0.58-2.76); P0.56]. Our data have
indicated that with the current protocol, patients given a relatively
high dose of CD3 cells (150106/kg) have a signiﬁcantly better
overall survival after transplantation than those given lower doses
of CD3 cells (150 106/kg).
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HLA-DRB1 ALLELE AND DRB1-DQB1 HAPLOTYPE FREQUENCY AS PRE-
DICTION CRITERION FOR THE DURATION OF AN UNRELATED BLOOD
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Identiﬁcation of at least one fully compatible unrelated blood
stem cell donor requires conﬁrmatory typing (CT) of 2-5 poten-
tially matched donors. We developed an algorithm, based on the
frequency of the HLA-DRB1 alleles and the estimated DRB1-
DQB1 haplotypes of the patient, which deﬁned the number of
potentially matched donors requested for CT. This strategy aimed
to result to a shorter UDS duration as well as to cost-effectiveness
in the process of a Unrelated donor search (UDS).
HLA-DRB1 allele frequencies were calculated based on the Na-
tional Marrow Donor Program dataset of 65752 individuals. HLA-
DRB1-DQB1 haplotype data were obtained from the German
National Donor Registry (ZKRD). HLA-DRB1 allele frequencies
within a given broad allele family (e.g. HLA-DRB1*11) were the
main point of consideration, since for most donors only a low
resolution typing was available. HLA-DRB1 alleles with a fre-
quency of 80-100% within their broad allele family were consid-
ered as very frequent. Alleles with a frequency of 30-79% within
their broad allele family as average, and a frequency of 0-29% as
rare. In addition, if the association of a particular HLA-DRB1
allele with the corresponding HLA- DQB1 allele was more fre-
quent than 80%, this DRB1-DQB1 haplotype was considered as
very common. A haplotype corresponding to 20% to 79% of a
given DRB1 allele was classiﬁed as average, whereas a haplotype
frequency of lower than 20% of a particular DRB1 allele was
considered as rare. Based on this algorithm, the probability to ﬁnd
a fully compatible donor for a patient was considered high, me-
dium or low. For the patients with high, medium or low probabil-
ity, three, 4 or 5 potentially matched unrelated donors were re-
quested for CT at the beginning of a UDS, respectively.
In a group of 794 patients, the average duration of UDS and the
average number of identiﬁed donors has been calculated. Eighty
percent of the searches showed a high, 7% a medium and 13% a
low probability to ﬁnd a fully compatible donor. The average UDS
duration was 55, 105, and 135 days in the three groups, respec-
tively. An average of 2.0, 1.6, and 1.0 donors were found in the
groups with high, medium, and low probability, respectively.
The algorithm used in our search unit, allows a prediction of
UDS duration and the estimation of the UDS success rate. A
variable number of potentially matched donors should be re-
quested for CT, which allows economising the UDS process with-
out prolongation of the UDS duration.
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Although allogeneic stem cell transplantation from a human
leukocyte antigen (HLA)-identical related donor offers a potential
cure for patients with acute myeloid leukemia (AML) not in re-
mission, a suitably matched related donor is unavailable for ap-
proximately two-thirds of patients. Recently, umbilical cord blood
from unrelated donors have been used as an alternative stem cell
source for adult patients with AML. Here, we report our clinical
results of unrelated cord blood transplantation (CBT) after my-
eloablative conditioning for 30 adult patients with AML not in
remission. Between August 1998 and November 2005, 30 adult
patients with AML not in remission were treated with unrelated
CBT at The Institute of Medical Science, University of Tokyo.
Diagnoses at transplantation included de novo AML (n14) and
MDS-related secondary AML (n16). All patients received four
fractionated 12 Gy total body irradiation and chemotherapy as
myeloablative conditioning. 27 patients received standard cyclo-
sporine (CyA) and methotrexate, and 3 patients received CyA only
as a graft-versus-host disease (GVHD) prophylaxis. Among the
patients the median age was 45.5 years (range, 19-55 years), the
median weight was 55 kg (range, 36-76 kg) and the median number
of cryopreserved nucleated cells was 2.43  107/kg (range, 1.16-
5.29  107/kg). 28 patients had myeloid reconstitution and the
median time to more than 0.5  109/L absolute neutrophil count
was 21.5 days. A self-sustained platelet count more than 50 
109/L was achieved in 23 patients at a median time of 42 days.
Acute GVHD above grade II occurred in 15 of 28 evaluable
patients and chronic GVHD occurred in 17 of 23 evaluable pa-
tients. Among 17 chronic GVHD patients, 7 patients were exten-
sive type. 16 patients are alive and free of disease at between 280
and 2937 days after transplantation. With a median follow-up of
2013 days, the probability of disease-free survival at 5 years was
51.8%. These results suggest that adult patients with AML not in
remission should be considered as candidates for CBT.
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There is a signiﬁcant amount of morbidity and mortality follow-
ing myeloablative UCBT, in part secondary to a log less TNC/
CD34 cells/kg infused compared to matched BM or PBSC
(Cairo et al, Blood, 1997). RI conditioning followed by BM or
matched PBSC may potentially reduce the incidence of TRM and
the late effects associated with myeloablative regimens without
increasing the risk of graft failure or relapse (Satwani/Cairo,
BBMT, 2005). Since UCB has a log less cells, it remains to be
determined whether RI conditioning will be as successful when
combined with UCBT. We currently report the results of RI-
UCBT in 21 pediatric pts, median age 7.5 years (0.33-20 yrs). HLA
match: 4/6 -13, 5/6-5, 6/6-3. Malignant diseases n14, Hodgkin’s
disease n5 (CR2-2, SD -1 and PD-2), NHL n2 (ALCL-PR1
and DLBCL-SD), CML (CP-1), AML n3 (CR1-2and CR2-1),
MDS n3 and non-malignant diseases n7, HLH-2, WAS-1,
B-Thal-1, SAA -1, SCID’s-2. RI conditioning consisted of ﬂudara-
bine (150-180mg/m2)with either busulfan (8mg/kg)ATG (n16)
or cyclophosphamideATGetoposide (n5). GHVD prophy-
laxis consisted of FK-506 and MMF (Osunkwo/Cairo, BBMT,
2004). The median TNC/ kg was 3.58107(0.92-22.61) and the
median CD34 cell dose/kg was 2.54105(0.34- 9.57). The me-
dian time for neutrophil and platelet engraftment was 17.5 days
(1-47) and 52 days (6-170), respectively. There were 6 primary
graft failures (1 CML, 1 b-Thal, 2 HLH, 1 MDS, and 1 AML), 4/6
who were regrafted with myeloablative conditioning followed by a
UCBT achieved100% engraftment. In the remainder 14 evaluable
patients the donor chimerism at 30 and 180 days was 74 20% and
90 10%, respectively. The probability of developing grade II-IV
aGVHD and cGVHD was 28.6% and 16.7%, respectively. Inci-
dence of TRM was 14%. The 2yr OS in all patients was 59.8%
(CL95: 37.9-81.6). The 2yr OS for patients with average risk
malignancy was 77.8% (CL95: 50.6-100) and poor risk malignancy
was 20.2% (CL95: 0-55.1). These preliminary results indicate that
despite a log less TNC/CD34 cells/kg infused compared to
matched BM or PBSC, RI-UCBT may result in rapid hematopoi-
etic reconstitution while decreasing TRM compared to myeloab-
lative UCBT and be associated with high donor chimerism. Pa-
tients with some diseases such as CML, b-Thal, and HLH may
require increased intensity of conditioning. Further follow-up is
required to evaluate long-term effects in pediatric patients follow-
ing RI-UCBT.
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We have reported the feasibility of reduced-intensity cord blood
transplantation (RICBT) for elderly patients with hematological
malignancies at the last Tandem meeting (Abstract#18). Despite of
its efﬁcacy, treatment-related mortality (TRM) at day 100 post-
transplant was considerably high (50%). Our preliminary data
suggested that tacrolimus (TAC) as GVHD prophylaxis reduced
TRM. Therefore, we conducted a retrospective analysis of 35
consecutive patients55 years who underwent RICBT with single
CB unit at our institute using TAC as GVHD prophylaxis from
Jan. 2004 to Apr. 2006. Diagnoses were AML/MDS (21), CML (4),
ALL (6), and ML (4), 11 of them were categorized as standard risk
(those who were in CR, CP, and untreated MDS) and 24 of them
were as high risk diseases (other than standard). Median total
nucleated cell and CD34 cell numbers were 2.25 10E7 /kg
(range, 1.82-3.6) and 0.78 10E7 /kg (range, 0.11-1.9), respec-
tively. Thirty-two patients (91%) were conditioned with 125 mg/
sqm of ﬂudarabine, 80 mg/sqm of melphalan, and 4 Gy of TBI, and
the other 3 were with slight modiﬁcation. TAC was started at day
-1 of transplant at 0.03 mg/kg for 24 hr. Thirty-three of them were
treated with TAC alone, and 2 were with TAC and mycophenolate
mofetile. Eight patients died before day 28. Among the remaining
27 patients, 24 (88.9%) of them achieved neutrophil engraftment
at a median 19 days (range, 12-33). Fifteen out of 25 (60%) and 9
out of 17 (53%) evaluable patients experienced acute GVHD
(grade II-IV: 12, III-IV: 8) and chronic GVHD (limited: 5, exten-
sive: 4), respectively. Twelve patients (37%) died before day 100
post-transplant. At the median 420 days post-transplant (range,
54-773), 18 survived, with 16 being disease-free. Overall (OS) and
progression-free survival at 1 year post-transplant were 54.6% and
41.3%, respectively. Remarkably, OS at 1 year post-transplant for
those with standard risk diseases was 91%, whereas it was 38% for
those with high risk. Among 17 deaths observed, 6 were from
disease progression and the other 11 were from non-relapse causes.
Multivariate analyses revealed that age older than 60, poor ECOG
performance status (2) before transplant, higher disease risk were
associated with an increased risk for mortality. To conclude,
RICBT with TAC is a feasible approach for elderly patient, espe-
cially for those with standard risk diseases. Longer follow-up is
necessary to further evaluate the curability of this approach.
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Clinical trials using unrelated donors are accepted choices world-
wide for patients in need of transplant but lacking HLA-matched
related donors. To study the outcome we reviewed our experience
with 28 Thai pediatric patients (22 male; 6 female) given hemato-
poietic stem cell transplantations from unrelated donors (UD-
HSCT) selected using DNA high-resolution typing of both HLA
class I and II loci, from May 2001 to September 2006. Median age
and weight were 7 years 7 months (1 y 3 m-16 y 9 m), and 24.5 kg
(7.8-68.8), respectively. Twenty patient/donor pairs (71.43%) were
fully matched; eight (28.57%) were 5/6 matched. Patients had
either non-malignant (n23) or malignant (n5) diseases. Among
non-malignant group there were beta-thalassemia major (n16),
adrenoleukodystrophy (n3), severe aplastic anemia (n2), Wis-
kott-Aldrich syndrome (n1), and Griscelli syndrome (n1); while
there were acute lymphoblastic leukemia (n2), chronic myeloid
leukemia (n1), juvenile chronic myelomonocytic leukemia (n1),
and relapsed Hodgkin disease (n1) in malignant group. Besides
umbilical cord blood transplant (CBT) recipients (n3) for whom
graft-versus-host disease (GvHD) prophylaxis with mainstay cyclo-
sporine was used, GvHD prophylaxis for bone marrow (BMT) and
peripheral blood stem cell transplant (PBSCT) composed of cy-
closporine plus short-term methotrexate in ﬁrst 12 recipients;
tacrolimus plus short-term methotrexate in last 13. Median num-
bers of infused CD34 cells were 5.15106/kg (1.24-33.6) in
BMT (n17), 6.8106/kg (3.91-17.17) in PBSCT (n8), and
3105/kg (2.26-25) in CBT (n3). The probability of hematopoi-
etic recovery at day 30 was 85.71%. Of the engrafted patients
(n25) the cumulative probability of acute and chronic GvHD
were 32 and 16%, respectively. Ten patients died of transplant-
related complications. The probability of transplant-related mor-
tality (TRM) at 30 days, 100 days, 1 year, and 2 years were 10.71,
28.57, 28.57, and 35.71%, respectively. Median follow-up time for
surviving patients was 1 year 6 months (2 m-5 y 4 m). Overall (OS)
and disease-free survival (DFS) rates were 64.29 and 57.14%,
respectively. Of the beta-thalassemia patients group (n16) the OS
and DFS rates were superior; 81.25 and 75%, respectively. UD-
HSCT with donor selection based on high-resolution HLA typing
is associated with low incidence of graft failure and GvHD. This
observed outcome is favorable and comparable to that of children
transplanted from HLA-identical siblings.
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